Pfizer Inc. $PFE Stock: Bokf Na Reduces Stake

Bokf Na trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 27.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 59,498 shares of the biopharmaceutical company’s stock after selling 22,547 shares during the quarter. Bokf Na’s holdings in Pfizer were worth $1,697,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in PFE. Retirement Wealth Solutions LLC increased its stake in shares of Pfizer by 144.6% in the third quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 509 shares during the period. Evolution Wealth Management Inc. boosted its position in Pfizer by 132.2% during the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 566 shares during the period. Keb Asset Management LLC acquired a new stake in Pfizer during the 2nd quarter worth approximately $26,000. Field & Main Bank acquired a new stake in Pfizer during the 2nd quarter worth approximately $27,000. Finally, Bullseye Investment Management LLC bought a new stake in Pfizer during the 2nd quarter worth approximately $28,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Up 1.8%

PFE opened at $30.48 on Friday. The company has a fifty day moving average price of $28.55 and a two-hundred day moving average price of $26.79. Pfizer Inc. has a 1-year low of $23.62 and a 1-year high of $30.67. The company has a market cap of $173.73 billion, a P/E ratio of 40.11, a price-to-earnings-growth ratio of 2.07 and a beta of 0.32. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. The company had revenue of $15.03 billion for the quarter, compared to analysts’ expectations of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business’s revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts predict that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 5.6%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer’s dividend payout ratio is 226.32%.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported that its Phase 3 MagnetisMM-32 trial of ELREXFIO met its primary endpoint in patients with relapsed or refractory multiple myeloma. The result supports another potential growth driver for Pfizer’s oncology portfolio. The FDA also expanded the use of TALZENNA plus XTANDI for certain men with metastatic hormone-sensitive prostate cancer, increasing the commercial opportunity for the combination. Pfizer cancer trial and FDA approval article
• Positive Sentiment: New real-world data from China showed continued momentum for lorlatinib in lung cancer treatment, potentially reinforcing the drug’s adoption and durability outside clinical-trial settings. Lorlatinib China study article
• Positive Sentiment: Pfizer launched a Phase 1 trial for Alzheimer’s candidate PF-08161842, adding a new early-stage asset to its pipeline. Although the program is years from potential commercialization, it gives investors another source of long-term optionality. PF-08161842 Alzheimer’s trial article
• Neutral Sentiment: Investors are focused on Pfizer’s third-quarter earnings report, scheduled for November 3. Attention will center on whether non-COVID products and pipeline progress can offset continuing declines in pandemic-related revenue. Pfizer Q3 earnings outlook article
• Negative Sentiment: Analysts remain cautious ahead of earnings, while commentary highlights that Pfizer’s nearly 6% dividend yield exceeded free cash flow in the prior year. That raises questions about long-term payout coverage, even though the dividend remains attractive to income-focused investors. Pfizer dividend safety article

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on PFE shares. Bank of America decreased their price target on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Cantor Fitzgerald lifted their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a report on Thursday, October 8th. Scotiabank boosted their price objective on shares of Pfizer from $30.00 to $33.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 6th. HSBC boosted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock a “hold” rating in a research note on Thursday, September 10th. Finally, JPMorgan Chase & Co. increased their price objective on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 9th. Five research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $28.65.

About Pfizer

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.